Following a landmark close to 2023, the cell and gene therapy field has continued its impressive momentum in the first quarter of 2024 with several notable approvals and strong growth in all stages of clinical development. 

The field earned the approval of three new therapies – a CAR-T therapy for myeloma in China, an AAV gene therapy for hemophilia B in Canada, and an autologous cell therapy for melanoma in the US. 

Excitingly, there are now more than 4,000 gene, cell, and RNA therapies in development. We also recorded significant increases in the number of therapies across all three phases of development in the clinical pipeline, with notable growth (11%) in Phase I programs. 

While overall dealmaking rebounded with a 34% increase in transactions, the start-up financing landscape continued to face challenges. Both the number and total value of seed and Series A rounds declined in Q1. Nevertheless, the breadth of progress across approvals, clinical development, and the broader ecosystem underscores the progress, promise, and vitality of cell and gene therapy. 

For the full report, please download the PDF version at the top of this page in collaboration with ASGCT.